The CEO's sustained selling over the past month, including this new Form 144, is a strong negative signal. Despite bullish analyst consensus, the insider's consistent unloading of shares suggests a lack of confidence in near-term valuation or upcoming catalysts. Traders should monitor for any negative news or guidance changes and consider reducing positions or hedging.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $65.97entry
- T+1 · 5mo ago +2.32%α +1.54% · $67.50
- T+5 · 4mo ago −5.55%α −6.94% · $62.31
- T+20 · 4mo ago −17.92%α −17.64% · $54.15
- T+60 · 8w ago −18.27%α −22.65% · $53.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Dennis Mulroy filed a Form 144 on June 26, 2026, indicating intent to sell 10,000 shares of AnaptysBio common stock, valued at approximately $608,183. This filing is part of a sustained selling pattern: Mulroy has sold over 300,000 shares in the past month, totaling roughly $18 million, with the latest tranche sourced from a stock option exercise.
Key Facts
- CEO Dennis Mulroy filed Form 144 to sell 10,000 shares valued at ~$608,183.
- The proposed sale follows a stock option exercise on June 26, 2026.
- Mulroy has sold over 300,000 shares since May 15, 2026, totaling approximately $18 million.
- Prior sales include: 35,000 shares on June 11 ($1.85M), 22,491 on June 5 ($1.15M), and 20,000 on June 3 ($1.02M).
- The company has a market cap of $1.9B and 94% analyst bullish consensus.
Financial Impact
CEO selling ~$608K in a single proposed transaction, part of a ~$18M selling wave over the past month.
Risk Factors
- CEO selling may signal deteriorating fundamentals or upcoming negative catalysts.
- Continued insider selling could pressure the stock price and erode investor confidence.
- The selling wave may indicate that the CEO believes the stock is fully valued or overvalued.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006565 |
| Document: 0001950047-26-006565-index.html | 0001950047-26-006565 |
| Document: 0001950047-26-006565.txt | 0001950047-26-006565 |
Track record
28 reports on ANAB
10 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Viewing Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers